BioMarin Licenses Fabry Disease Therapy From GC Biopharma, Hanmi Pharm

• BioMarin entered an exclusive license agreement with GC Biopharma and Hanmi Pharm for investigational Fabry disease therapy HM15421/GC1134A.
• The deal grants worldwide rights excluding Korea, where GC and Hanmi retain commercialization rights.
• Terms include $70 million upfront, up to $405 million in development and commercial milestones, and tiered royalties on net sales.
• The long-acting, subcutaneous enzyme replacement therapy is in a Phase 1/2 trial.
• Following that study, BioMarin will assume sole responsibility for subsequent clinical development, manufacturing and commercialization outside Korea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290845PR_NEWS_USPR_____SF84234) on October 29, 2026, and is solely responsible for the information contained therein.